Dexrazoxane increased the maximum cardiotoxicity-free anthracycline dose (431.8 vs 268.2 mg/m2) and minimally improved projected survival (75.4% vs 71.9%) in pediatric solid tumor patients.
Systematic Review
Does dexrazoxane reduce anthracycline-induced cardiotoxicity in pediatric solid tumor patients?
Dexrazoxane significantly increases the cardiotoxicity-free anthracycline dose threshold in pediatric solid tumor patients, though lifelong cardiac monitoring remains necessary due to linearly increasing cardiotoxicity risk over time.
Absolute Event Rate: 75.4% vs 71.9%
Cardiotoxicity is a dose-limiting and potentially lethal complication of anthracycline administration. Previous studies failed to determine definitive toxic doses or cardioprotective factors. Current dosing strategies may utilize unnecessarily high anthracycline doses, such that survival benefit may not outweigh increased toxicity rates. A systematic review of randomized controlled trials and prospective/retrospective studies investigating anthracycline treatment in pediatric solid tumors was performed from PubMed/MEDLINE and Cochrane databases. Generalized linear models mapping survival, cardiotoxicity, and cardiotoxicity-free survival adjusted for male-to-female ratio, follow-up time, and concomitant chemotherapeutic drugs or cardioprotective agents (dexrazoxane) were generated using R. Survival rose linearly with increasing cumulative anthracycline dose whereas cardiotoxicity demonstrated exponential increases both without (dose, >200 mg/m) and with (dose, >400 mg/m) dexrazoxane. Maximum cardiotoxicity-free survival was 268.2 mg/m without and 431.8 mg/m with dexrazoxane. Despite increasing cardiotoxicity-free dose by >150 mg/m, dexrazoxane minimally improved projected survival (71.9% vs. 75.4%). Cardiotoxicity increased linearly as a function of follow-up time with rates doubling from 5 to 20 years, without evidence of plateau. On the basis of our model, current dosing regimens-doxorubicin doses >375 mg/m without dexrazoxane-overvalue increased anthracycline administration and may contribute to devastating cardiotoxicity. The linear increase of cardiotoxicity without evidence of plateau confirms the necessity for lifelong cardiac monitoring.
Liesse et al. (Fri,) conducted a systematic review in Pediatric solid tumors. Dexrazoxane vs. Without dexrazoxane was evaluated on Projected survival. Dexrazoxane increased the maximum cardiotoxicity-free anthracycline dose (431.8 vs 268.2 mg/m2) and minimally improved projected survival (75.4% vs 71.9%) in pediatric solid tumor patients.